SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. )*
Molecular Data Inc.
(Name of Issuer)
Class A ordinary shares, par value US$0.00005 per share
(Title of Class of Securities)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
CUSIP number 60852L106 has been assigned to the American Depositary Shares (ADSs) of the issuer, which are quoted on The Nasdaq Stock Market LLC under the symbol MKD. Each ADS represents three Class A ordinary shares of the issuer.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 60852L106||Page 2 of 5|
Names of reporting persons
TB Alternative Assets Ltd
Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐
SEC use only
Citizenship or place of organization
Number of shares beneficially owned by
each reporting person
Sole voting power
Shared voting power
Sole dispositive power
Shared dispositive power
Aggregate amount beneficially owned by each reporting person:
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
Percent of class represented by amount in Row (9)
Type of reporting person (see instructions)
IA, Investment Adviser
Number of shares beneficially owned as of 31 Dec 2020.
Calculation is based on 345,127,023 outstanding ordinary shares for all classes as of 31 Dec 2020.
|SCHEDULE 13G||Page 3 of 5|
|Item 1(a)|| |
Name of issuer: Molecular Data Inc.
|Item 1(b)|| |
Address of issuers principal executive offices 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 Peoples Republic of China
2(a) Name of person filing: TB Alternative Assets Ltd
This statement is filed by TB Alternative Assets Ltd, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, with respect to the portion of the Class A Ordinary Shares (as defined by 2(d) below) held by Trustbridge Partners IV LP, a Cayman business company that is controlled by TB Alternative Assets Ltd. TB Alternative Assets Ltd acts as the investment adviser of Trustbridge Partners IV LP.
2(b) Address or principal business office or, if none, residence: c/o Maples Corporate Services Limited, Ugland House, Grand Cayman, Cayman Islands, KY1-1104
2(c) Citizenship: Cayman Islands
2(d) Title of class of securities: Class A Ordinary Shares, $0.0005 par value per share**
2(e) CUSIP No.: CUSIP number 60852L106 has been assigned to the American Depositary Shares (ADSs) of the issuer, which are quoted on The Nasdaq Stock Market LLC under the symbol MKD. Each ADS represents three Class A ordinary shares of the issuer.
|Item 3.|| |
If this statement is filed pursuant to §§240.13d1(b) or 240.13d2(b) or (c), check whether the person filing is a:
|(a)||☐||Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);|
|(b)||☐||Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);|
|(c)||☐||Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);|
|(d)||☐||Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a8);|
|(e)||☒||An investment adviser in accordance with §240.13d1(b)(1)(ii)(E);|
|(f)||☐||An employee benefit plan or endowment fund in accordance with §240.13d1(b)(1)(ii)(F);|
|(g)||☐||A parent holding company or control person in accordance with §240.13d1(b)(1)(ii)(G);|
|(h)||☐||A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);|
|(i)||☐||A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a3);|
|(j)||☐||A non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J);|
|(k)||☐||Group, in accordance with §240.13d1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J), please specify the type of institution:|
|Item 4.|| |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
Amount beneficially owned: 23,296,131
Percent of class: 6.75%
|SCHEDULE 13G||Page 4 of 5|
Number of shares as to which the person has:
Sole power to vote or to direct the vote: 23,296,131
Shared power to vote or to direct the vote: 0
Sole power to dispose or to direct the disposition of: 23,296,131
Shared power to dispose or to direct the disposition of: 0
|Item 5.|| |
Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].
Dissolution of a group requires a response to this item.
|Item 6.|| |
Ownership of More than 5 Percent on Behalf of Another Person.
|Item 7.|| |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|Item 8.|| |
Identification and Classification of Members of the Group.
|Item 9.|| |
Notice of Dissolution of Group.
|Item 10.|| |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.
|SCHEDULE 13G||Page 5 of 5|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.